CAS: 133040-01-4; (E)-4-((2-Butyl-5-(2-Carboxy-3-(Thiophen-2-yl)Prop-1-En-1-yl)-1H-Imidazol-1-yl)Methyl)Benzoic Acid

该化合物是非甲状腺素乙型受体敌体(ARB),有选择性地针对AT1受体子型亚型,主要用于高血压管理,通过屏蔽血管受体素II的血管受体抑制和阿多松内分泌效应,提供有效的血压控制.Eprosartan具有高生物利用率和线性药性动能特征,通过细胞化P450酶来减少新陈代谢,降低药物相互作用的风险.它独特的化学结构缺乏双苯四氮细胞,与其他亚血压相区别.该化合物在尿液和肉质方面基本上没有变化,因此适合肝损伤患者.临床研究显示它能以有利的安全特征减少心血管风险.

结构式图片

上下游产品

CAS号133040-03-6 4-[((2-丁基-5-甲酰基... | CAS号143468-96-6 3-乙氧基-3-氧代-2-(噻... | CAS号133040-06-9 (E)-3-[2-丁基-1-[... | CAS号2417-72-3 4-溴甲基苯甲酸甲酯 | CAS号83857-96-9 2-正丁基-5-氯-4-甲酰基咪唑 | CAS号133040-02-5 2-butyl-4-chlor... | CAS号133486-13-2 methyl 4-[[2-bu... | CAS号1104528-98-4 (E)-α-[[2-butyl... | CAS号133040-04-7 2-butyl-1-(4-ca...

合成工艺路线路线简述

  • 合成目标产物 Eprosartan 主要起始原料 Methyl 4-[(2-Butyl-5-Formyl-1H-Imidazol-1-yl)Methyl]Benzoate And 2-Carbethoxy-3-(2-Thienyl)Propanoic Acid
  • (文献来源)合成步骤主要原料 Methyl 4-[(2-Butyl-5-Formyl-1H-Imidazol-1-yl)Methyl]Benzoate 和 2-Carbethoxy-3-(2-Thienyl)Propanoic Acid
甲基(E)-3-[2-丁基-1-[(4-甲氧羰基苯基)甲基]咪唑-5-基]-2-(2-噻吩基甲基)-2-丙烯酸酯置于sodium Hydroxide体系中,用 乙醇 用作溶剂,化学反应 4.0H,以58%的收率获得依普罗沙坦
参考文献:2-Butyl-4-Iodoimidazole-5-Carboxaldehyde:一种用于合成高度官能化咪唑的多功能中间体
标题:2-Butyl-4-Iodoimidazole-5-Carboxaldehyde:一种用于合成高度官能化咪唑的多功能中间体
摘要:摘要 描述了2-丁基-4-碘咪唑-5-甲醛1的简便制备.该中间体在合成高度功能化的咪唑方面的多功能性通过两种有效和选择性血管紧张素 Ii 受体拮抗剂的合成得到证明.
Doi:10.1080/00397919308011184

海关参考信息

专利信息


专利号:US-10925977-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

专利号:US-10973847-B2
优先权日:2017-06-30
标题 :Core-to-surface polymerization for the synthesis of star polymers and uses thereof
发明人:JOHNSON JEREMIAH A; GOLDER MATTHEW R
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:Disclosed are methods, compositions, reagents, systems, and kits to prepare star polymers, as well as compositions and uses thereof. Various embodiments show that synthesis of these polymers contain low metal concentration to provide polymers for diverse biomedical applications including in vivo applications.

专利号:US-10005720-B2
优先权日:2013-04-05
标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

专利号:US-8431712-B2
优先权日:2004-02-09
标 题 :Methods for the synthesis of pyridoxamine
发明人:KHALIFAH RAJA G; KEILITZ ROLAND; KOELLNER CHRISTOPH; DEGENHARDT THORSTEN; BRAND STEPHEN ROBERT
权利人:KHALIFAH RAJA G; KEILITZ ROLAND; KOELLNER CHRISTOPH; DEGENHARDT THORSTEN; BRAND STEPHEN ROBERT; NEPHROGENEX INC
摘要:The invention provides non-oxidative methods for the large scale manufacture of pyridoxamine (I) (4-aminomethyl-3-hydroxy-5-hydroxymethyl-2-methylpyridine): n nand salts thereof.n nThe invention also provides intermediate compounds for the synthesis of pyridoxamine, as well as compositions and methods for the treatment and/or prevention of conditions associated with the formation of post-Amadori advanced glycation end-products.

专利号:US-2003050305-A1
优先权日:2000-05-22
标题:Thromboxane inhibitors, compositions and methods of use
发明人:TEJADA INIGO SAENZ DE
摘要:The present invention describes methods for treating or preventing sexual dysfunctions in males and females, and for enhancing sexual responses in males and females by administering a therapeutically effective amount of at least one thromboxane inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The male or female may preferably be diabetic. The present invention also provides novel compositions comprising at least one thromboxane inhibitor, and, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and, optionally, at least one therapeutic agent, such as, vasoactive agents, nonsteroidal antiinflanmmatory compounds (NSAIDs), selective cyclooxygenase-2 (COX-2) inhibitors, anticoagulants, angiotensin converting enzymes (ACE) inhibitors, angiotensin II receptor antagonists, renin inhibitors, and mixtures thereof. The present invention also provides methods for treating or preventing ischemic heart disorders, myocardial infarction, angina pectoris, stroke, migraine, cerebral hemorrhage, cardiac fatalities, transient ischaemic attacks, complications following organ transplants, coronary artery bypasses, angioplasty, endarterectomy, atherosclerosis, pulmonary embolism, bronchial asthma, bronchitis, pneumonia, circulatory shock of various organs, nephritis, graft rejection, cancerous metastases, pregnancy-induced hypertension, preeclampsia, eclampsia, thrombotic and thromboembolic disorders, intrauterine growth, gastrointestinal disorders, renal diseases and disorders, disorders resulting from elevated uric acid levels and dysmenorrhea, and for inhibiting platelet aggregation or platelet adhesion or relaxing smooth muscles.

专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.
厦门环华有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.china-sinoway.com
企业联系电话:86-592-5853819👤
📞厦门环华有限公司 ⚠️参考联系方式
联系人:谢先生
电话:86-592-5853819

传真:86-592-5854960
邮箱:xie@china-sinoway.com
通信地址: 厦门厦禾路839号汇成商业中心16楼
邮编: 361004
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:厦门厦禾路839号汇成商业中心16楼
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Takezako T, Unal H, Karnik SS, Node K. Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism. Pharmacol Res. 2017 Sep;123:40-50. doi: 10.1016/j.phrs.2017.06.013. Epub 2017 Jun 23. Review.
2: Yang R, Luo Z, Liu Y, Sun M, Zheng L, Chen Y, Li Y, Wang H, Chen L, Wu M, Zhao H. Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450. Curr Drug Metab. 2016;17(7):681-91. Review. doi: 10.5853/jos.2015.01102. Epub 2015 Dec 17. Review.
4: Zaiken K, Hudd TR, Cheng JW. A review of the use of angiotensin receptor blockers for the prevention of cardiovascular events in patients with essential hypertension without compelling indications. Ann Pharmacother. 2013 May;47(5):686-93. doi: 10.1345/aph.1R273. Epub 2013 Apr 12. Review. Review. Czech. doi: 10.1124/pr.112.007278. Print 2013 Apr. Review. Review. Review. Czech. Review. French. doi: 10.2147/VHRM.S22595. Epub 2012 Feb 28. Review.

合成参考文献


参考文献:10.1093/eurjhf/hfq001
摘要:Hartog JW, van de Wal RM, Schalkwijk CG, Miyata T, Jaarsma W, Plokker HW, van Wijk LM, Smit AJ, van Veldhuisen DJ, Voors AA. Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction. Eur J Heart Fail. 2010 Apr;12(4):397–403. doi: 10.1093/eurjhf/hfq001.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知